Cara Therapeutics Inc
NASDAQ:CARA

Watchlist Manager
Cara Therapeutics Inc Logo
Cara Therapeutics Inc
NASDAQ:CARA
Watchlist
Price: 18.2486 USD 243.02% Market Closed
Market Cap: 83.4m USD

Operating Margin
Cara Therapeutics Inc

-740.1%
Current
-493%
Average
6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-740.1%
=
Operating Profit
-52.8m
/
Revenue
7.1m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Cara Therapeutics Inc
NASDAQ:CARA
83.4m USD
-740%
US
Eli Lilly and Co
NYSE:LLY
1T USD
44%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
495.1B USD
27%
CH
Roche Holding AG
SIX:ROG
271.3B CHF
34%
UK
AstraZeneca PLC
LSE:AZN
218.9B GBP
24%
US
Merck & Co Inc
NYSE:MRK
276.1B USD
38%
CH
Novartis AG
SIX:NOVN
218.1B CHF
33%
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
42%
IE
Endo International PLC
LSE:0Y5F
213.9B USD
11%
US
Pfizer Inc
NYSE:PFE
143.8B USD
29%
No Stocks Found

Cara Therapeutics Inc
Glance View

Market Cap
83.4m USD
Industry
Pharmaceuticals

CARA Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors (KORs). The company is headquartered in Stamford, Connecticut and currently employs 84 full-time employees. The company went IPO on 2014-01-31. The firm is developing a class of product candidates KORSUVA (CR845/difelikefalin), which is a KOR agonist that targets the body’s peripheral nervous system, as well as certain immune cells. The firm is also conducting preclinical studies and clinical trials of CR845/difelikefalin-based product candidates. The firm also initiated a pharmacokinetic safety trial of multiple doses of Oral CR845 in hemodialysis patients to define bioequivalent tablet strengths to inform its ability to develop an oral tablet formulation for moderate-to-severe uremic pruritus. CR701 is a peripherally restricted, mixed-CB1/CB2 receptor agonist that selectively interacts with these cannabinoid receptor subtypes, with no off-target activities.

CARA Intrinsic Value
13.7344 USD
Overvaluation 25%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-740.1%
=
Operating Profit
-52.8m
/
Revenue
7.1m
What is the Operating Margin of Cara Therapeutics Inc?

Based on Cara Therapeutics Inc's most recent financial statements, the company has Operating Margin of -740.1%.

Back to Top